Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cellyan Biotechnology CoHKPD -2.82%21 Return-on-Tangible-Equity is 6.19% as of Sep. 2025, which is 89% below its 10-year median of 55.38. GuruFocus rates HKPD with a GF Scoreâ„¢ of 21/100. The stock has 2 warning signs investors should review. Among 111 Medical Distribution companies, Cellyan Biotechnology Co ranks worse than 87.39% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Cellyan Biotechnology Co's annualized net income for the quarter that ended in Sep. 2025 was $0.31 Mil. Cellyan Biotechnology Co's average shareholder tangible equity for the quarter that ended in Sep. 2025 was $4.97 Mil. Therefore, Cellyan Biotechnology Co's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2025 was 6.19%.
The historical rank and industry rank for Cellyan Biotechnology Co's Return-on-Tangible-Equity or its related term are showing as below:
HKPD'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -13.85 Med: 55.38 Max: 171.77
Current: -13.85
During the past 3 years, Cellyan Biotechnology Co's highest Return-on-Tangible-Equity was 171.77%. The lowest was -13.85%. And the median was 55.38%.
HKPD's Return-on-Tangible-Equity is ranked worse than 87.39% of 111
companies
in the Medical Distribution industry
Industry Median: 8.81
vs HKPD: -13.85
Cellyan Biotechnology Co (NAS:HKPD) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Cellyan Biotechnology Co Return-on-Tangible-Equity Related Terms
Cellyan Biotechnology Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Cellyan Biotechnology Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellyan Biotechnology Co Return-on-Tangible-Equity Chart
HKPD vs COSM, SNYR, YI: Return-on-Tangible-Equity Comparison
For the Medical Distribution subindustry, Cellyan Biotechnology Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cellyan Biotechnology Co Return-on-Tangible-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cellyan Biotechnology Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Cellyan Biotechnology Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Sep. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 6.19% mean?
Cellyan Biotechnology Co (HKPD) has a Return-on-Tangible-Equity of 6.19% as of Sep. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Cellyan Biotechnology Co and its competitors. This is 89% below median its historical median of 55.38. According to the industry distribution chart, Cellyan Biotechnology Co ranks #97 out of 111 companies in the Medical Distribution industry, placing it in the top 87.4%.
Is Cellyan Biotechnology Co's Return-on-Tangible-Equity too high?
Cellyan Biotechnology Co's current Return-on-Tangible-Equity of 6.19% is 89% below median its 10-year median of 55.38. The Medical Distribution industry median Return-on-Tangible-Equity is 8.81. Cellyan Biotechnology Co's value of 6.19% is 29.7% below this industry median. Based on the distribution chart, Cellyan Biotechnology Co ranks #97 out of 111 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Cellyan Biotechnology Co has a GF Scoreâ„¢ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Cellyan Biotechnology Co's Return-on-Tangible-Equity compare to COSM and SNYR?
According to the Medical Distribution industry distribution chart, Cellyan Biotechnology Co ranks #97 out of 111 companies for Return-on-Tangible-Equity. This places Cellyan Biotechnology Co in the lower half of its industry. The industry median Return-on-Tangible-Equity is 8.81. Cellyan Biotechnology Co's value of 6.19% is 29.7% below this benchmark. While the company's 10-year median is 55.38 vs. the industry median of 8.81, Cellyan Biotechnology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Distribution company?
The median Return-on-Tangible-Equity among Medical Distribution companies is 8.81, based on 111 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cellyan Biotechnology Co's current Return-on-Tangible-Equity of 6.19% is 29.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Cellyan Biotechnology Co and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Equity is 8.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cellyan Biotechnology Co's current Return-on-Tangible-Equity is 6.19%, which is 89% below median its own 10-year median of 55.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellyan Biotechnology Co stock overvalued right now?
Cellyan Biotechnology Co (HKPD) has a current Return-on-Tangible-Equity of 6.19%. The current Return-on-Tangible-Equity is 6.19%, which is 89% below median its 10-year median of 55.38 and 29.7% below the Medical Distribution industry median of 8.81. Cellyan Biotechnology Co's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Cellyan Biotechnology Co (HKPD), the current Return-on-Tangible-Equity is 6.19% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
21GF Score
Get the complete analysis for HKPD
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKPD has been successfully added to your 
